NCT03547297TerminatedNot Applicable
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Alnylam Pharmaceuticals1 site in 1 country212 target enrollmentStarted: May 29, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Enrollment
- 212
- Locations
- 1
- Primary Endpoint
- Proportion of participants with current or past clinically symptomatic AHP with urinary aminolevulinic acid (ALA) or porphobilinogen (PBG) values above the upper limit of normal (ULN)
Study Overview
Brief Summary
This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •≥ 16 years of age
- •Recurrent and severe episodes of abdominal pain that last for at least 24 hours
- •At least 1 episode of severe abdominal pain that required an urgent healthcare visit in the past 12 months
- •Other symptoms related to AHP that your doctor will discuss with you
- •Willing and able to comply with protocol required assessments and provide written informed consent
Exclusion Criteria
- •Known diagnosis of AHP
- •Alternative explanation for abdominal pain with clinical response to treatment specific for alternative diagnosis
Outcomes
Primary Outcomes
Proportion of participants with current or past clinically symptomatic AHP with urinary aminolevulinic acid (ALA) or porphobilinogen (PBG) values above the upper limit of normal (ULN)
Time Frame: 12 months
Secondary Outcomes
- Proportion of participants with AHPs that contain likely pathogenic mutation(s) in the presence of urinary ALA or PBG values above the ULN(12 months)
- Proportion of patients with variants of unknown significance in the presence of urinary ALA and PBG values above the ULN(12 months)
- Correlation of biochemical and genetic test results with severity of disease measured by symptom frequency and severity in the participant questionnaire(12 months)
- Correlation of biochemical and genetic test results with severity of disease measured by healthcare utilization in the participant questionnaire(12 months)
- Proportion of patients with pathogenic mutation(s) in the presence of urinary ALA and PBG values above the ULN(12 months)
- Proportion of patients with negative genetic tests in the presence of urinary ALA or PBG values above the ULN(12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Not Applicable
Characteristics of Patients With COVID-19 in Meta State, ColombiaCOVIDSARS-CoV 2SARS PneumoniaSARS (Disease)SARS (Severe Acute Respiratory Syndrome)NCT04456426Hospital Departamental de Villavicencio
Completed
Not Applicable
Symptom Assessment With Patient SurveysCarcinomasAdenocarcinomaSquamous Cell CarcinomaNCT01135823Stanford University100
Completed
Not Applicable
HSV Oral Reactivation in ChildrenHSV-1HIVNCT01878279Dartmouth-Hitchcock Medical Center30
Completed
Not Applicable
The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU PatientsCritical IllnessNCT02634658University of Colorado, Denver120
Recruiting
Not Applicable
Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated BacteremiaStaphylococcus Aureus BacteremiaNCT06574399Fundación Pública Andaluza para la gestión de la Investigación en Sevilla1,000